Dr. Levi Waldron, assistant professor at the City University of New York School of Public Health, was recently awarded an R03 from the National Cancer Institute/NIH. This study aims to resolve controversy and uncertainty in the nature of ovarian cancer subtypes by two main approaches. First, subtype robustness and association to patient outcome are assessed by comparative meta-analysis using all relevant publicly available data. This will provide clarity on which definition of subtypes future research should focus on. Second, the likely ordering of subtype differentiation in tumor evolution is determined by analysis of the allele frequencies of subtype-associated DNA short variants in data from The Cancer Genome Atlas. This study will move the field of ovarian cancer research forward by resolving controversy around proposed subtypes using publicly available data, and by providing standardized definitions of subtype algorithms with documentation for their application to new patients.